GMAB News and Press, Genmab A/S From 04/25/23

2023-04-25 10:00:20 ET Summary Arbitration dismissal: Genmab's recent dismissal of its second arbitration case against Janssen regarding Darzalex Faspro royalties suggests that these royalties will likely cease after 2030. PDUFA date and pipeline focus: The market's attention shou...

2023-04-25 02:01:13 ET Summary To identify the most promising pharmaceutical companies with a market capitalization of more than $1 billion, we use an eight-step selection process, which will be discussed below. The following two articles will feature our list of the top 10 pharma...

2023-04-24 05:37:42 ET Genmab ( GMAB ) said it is filing a review of an award dismissing its claims in the second arbitration linked to a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Th...

Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today its decision to file a request for review of the award dismissing its claims in the second arbitration arising under i...

2023-04-21 13:34:59 ET Summary Genmab partnership: argenx and Genmab plan to collaborate to advance antibody therapies in immunology and oncology, leveraging proprietary technologies and sharing costs and profits equally. Q1 2023 sales expectations: Minor headwinds expected in efg...

2023-04-21 06:55:13 ET Genmab ( GMAB ) announced an award in the second arbitration arising under a license agreement with Johnson & Johnson's ( NYSE: JNJ ) unit Janssen Biotech over cancer drug daratumumab, sold as Darzalex. Genmab said the arbitral tribunal d...

Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB ) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc. (Janssen) for daratumumab...

2023-04-18 07:32:23 ET Genmab ( GMAB ) has reported worldwide Q1 net trade sales of $2.26B for DARZALEX (daratumumab) prescription medicine. Net trade sales were $1.91B in the U.S. and $1.07B in the rest of the world. Genmab receives royalties on the worldwide net sales of...

Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; April 18 , 2...

Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two differentiated targets are underway Genmab A/S (Nasdaq: GMAB) and argenx (Euro...